JNJ

Add to Watchlist

Advanced Chart

0.000

0.000(0.000%)

Overview
Forecast
Valuation

Line

Candle

YTD

High

157.9423

Open

154.740

VWAP

157.01

Vol

7.85M

Mkt Cap

378.48B

Low

154.500

Amount

1.23B

EV/EBITDA(TTM)

12.48

Total Shares

2.41B

385.14B

EV/OCF(TTM)

15.54

P/S(TTM)

4.19

Johnson & Johnson, through its subsidiaries, is engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company’s primary focus is products related to human health and well-being. It operates through two segments: Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. Products in this segment are distributed directly to retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment includes a broad portfolio of products used in the orthopedic, surgery, interventional solutions, and vision fields. These products are distributed to wholesalers, hospitals, and retailers, and used principally in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q2

FY2025Q3

FY2025Q4

22.85B

+1.78%

2.680

-4.96%

23.10B

+2.8%

2.688

+11.06%

23.46B

+4.17%

2.484

+21.79%

Estimates Revision

The market is revising Upward the revenue expectations for Johnson & Johnson (JNJ) for FY2025, with the revenue forecasts being adjusted by 1.5% over the past three months. During the same period, the stock price has changed by 3.55%.

Revenue Estimates for FY2025

Revise Upward

+1.5%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+0.33%

In Past 3 Month

Stock Price

Go Up

+3.55%

In Past 3 Month

15 Analyst Rating

8.21% Upside

Wall Street analysts forecast JNJ stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for JNJ is 170.21 USD with a low forecast of 159.00 USD and a high forecast of 185.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

8 Buy

7 Hold

0 Sell

Moderate Buy

8.21% Upside

Current: 157.300

Low

159.00

Averages

170.21

High

185.00

8.21% Upside

Current: 157.300

Low

159.00

Averages

170.21

High

185.00

Barclays

Matt Miksic

Hold

Maintains

$166 → $165

2025-04-17

Reason

Barclays

Matt Miksic

Price Target

$166 → $165

2025-04-17

Maintains

Hold

Reason

Barclays lowered the firm's price target on Johnson & Johnson to $165 from $166 and keeps an Equal Weight rating on the shares following the Q1 report. The company reported strong Pharma results offset by slower growth in MedTech, driven primarily by a series of one-timers and prior year issues, the analyst tells investors in a research note. The firm says J&J maintained its 2025 outlook despite additional deal dilution and tariff impact.

RBC Capital

Shagun Singh

Buy

Reiterates

$181

2025-04-16

Reason

RBC Capital

Shagun Singh

Price Target

$181

2025-04-16

Reiterates

Buy

Reason

Morgan Stanley

Terence Flynn

Hold

Maintains

$164 → $169

2025-04-16

Reason

Morgan Stanley

Terence Flynn

Price Target

$164 → $169

2025-04-16

Maintains

Hold

Reason

Morgan Stanley raised the firm's price target on Johnson & Johnson to $164 from $163 and keeps an Equal Weight rating on the shares. The firm adjusted its large cap pharma and biotech models for IQVIA trends as well as intra-quarter updates ahead of Q1 earnings reporting season for the group.

Raymond James

Jayson Bedford

Buy

Maintains

$162 → $164

2025-04-16

Reason

Raymond James

Jayson Bedford

Price Target

$162 → $164

2025-04-16

Maintains

Buy

Reason

Raymond James analyst Jayson Bedford lowered the firm's price target on Johnson & Johnson to $162 from $165 and keeps an Outperform rating on the shares ahead of quarterly results. While a portion of the tariff drama was dampened last Wednesday, the firm still expects Q1 MedTech earnings season to be eventful. The uncertainty tied to the impact of tariffs has tightened investment decisions, reduced the appetite for risk, and weighed on MedTech multiples. Based on Raymond James' math, the market is baking in an 8% cut to annual EPS for its large cap coverage. While the firm acknowledges a heightened level of uncertainty, its initial view is that this seems excessive.

Raymond James

Jayson Bedford

Buy

Maintains

$165 → $162

2025-04-14

Reason

Raymond James

Jayson Bedford

Price Target

$165 → $162

2025-04-14

Maintains

Buy

Reason

B of A Securities

Tim Anderson

Hold

Maintains

$171 → $159

2025-04-10

Reason

B of A Securities

Tim Anderson

Price Target

$171 → $159

2025-04-10

Maintains

Hold

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Johnson & Johnson (JNJ.N) is 14.91, compared to its 5-year average forward P/E of 16.36. For a more detailed relative valuation and DCF analysis to assess Johnson & Johnson 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Undervalued

5Y Average PE

16.36

Current PE

14.91

Overvalued PE

17.53

Undervalued PE

15.18

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Undervalued

5Y Average EV/EBITDA

13.05

Current EV/EBITDA

11.67

Overvalued EV/EBITDA

13.85

Undervalued EV/EBITDA

12.25

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Undervalued

5Y Average PS

4.51

Current PS

4.03

Overvalued PS

4.82

Undervalued PS

4.19

Financials

Annual

Quarterly

FY2025Q1

YoY :

+2.39%

21.89B

Total Revenue

FY2025Q1

YoY :

+2.81%

6.66B

Operating Profit

FY2025Q1

YoY :

+237.91%

11.00B

Net Income after Tax

FY2025Q1

YoY :

+238.81%

4.54

EPS - Diluted

FY2025Q1

YoY :

+18.56%

3.38B

Free Cash Flow

FY2025Q1

YoY :

-4.53%

66.43

Gross Profit Margin - %

FY2025Q1

YoY :

+4.40%

22.80

FCF Margin - %

FY2025Q1

YoY :

+230.09%

50.24

Net Margin - %

FY2025Q1

19.21

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

3.2M

USD

6-9

Months

0.0

USD

0-12

Months

930.1K

USD

Bought

0-3

0.0

USD

Months

3-6

147.2K

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

557.5K

Volume

6-9

Months

0.0

Volume

0-12

Months

2.8M

Volume

Bought

0-3

0.0

Volume

Months

3-6

2.4M

Volume

Months

6-9

0.0

Volume

Months

0-12

6.5M

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

215.0K

USD

3-6

Months

366.0K

USD

6-9

Months

40.5K

USD

0-12

Months

105.5K

USD

Bought

0-3

162.0K

USD

Months

3-6

161.0K

USD

Months

6-9

48.0K

USD

Months

0-12

72.5K

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

3.2M

USD

6-9

Months

0.0

USD

0-12

Months

930.1K

USD

Bought

0-3

0.0

USD

Months

3-6

147.2K

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

JNJ News & Events

Events Timeline

2025-05-06 (ET)

2025-05-06

13:35:55

FDA announces expanded use of unannounced inspections at foreign facilities

2025-05-05 (ET)

2025-05-05

15:13:10

Trump to sign order streamlining U.S. drug manufacturing regulations, WaPo says

2025-05-05

09:13:30

Trump urges drugmakers to accept lower prices on prescriptions, Bloomberg says

News

9.0

05-05Newsfilter

PinnedTREMFYA® (guselkumab) positioned to become the first and only IL-23 inhibitor to offer subcutaneous induction in ulcerative colitis as demonstrated in new data through 24 weeks

9.0

05-05NASDAQ.COM

PinnedJ&J Reports Positive Data From Long-term Extension Study Of TREMFYA In Ulcerative Colitis

9.0

05-05NASDAQ.COM

PinnedJohnson & Johnson Reports Positive Phase 3 ASTRO Study Data For TREMFYA In Ulcerative Colitis